EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-SNHL-04(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Sensorineural Hearing Loss (SNHL) is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Sensorineural Hearing Loss (SNHL) is caused by irreversible damage or degeneration of cochlear inner/outer hair cells, spiral ganglion neurons (SGNs), or the auditory nerve pathway, resulting from acoustic trauma, ototoxic exposure, ischemia, or age-related presbycusis.
Biological Rationale & Paracrine Action:
Explores targeted intratympanic (trans-tympanic round-window membrane permeation) and systemic intravenous delivery of clinical-grade umbilical cord mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to secrete neurotrophic and neuroprotective factors (BDNF, GDNF, NT-3), downregulate cochlear microvascular inflammation, and support spiral ganglion neuronal survival.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Individuals with documented chronic, bilateral or unilateral sensorineural hearing loss (mild-to-profound), sudden sensorineural hearing loss (SSNHL) refractory to high-dose systemic/intratympanic steroids, or noise-induced hearing deficits.
Mandatory Pre-Procedure Diagnostics:
Pure Tone Audiometry (PTA with air and bone conduction < 1 month old), Speech Discrimination / Word Recognition Scores (WRS), Tympanometry, Distortion Product Otoacoustic Emissions (DPOAE), Auditory Brainstem Response (ABR / BERA), and high-resolution 3T MRI of the cerebellopontine angle (CPA) and internal auditory canal (IAC).
Strict Safety Exclusion Parameters:
Conductive hearing loss (e.g., ossicular disruption, otosclerosis, chronic suppurative otitis media), acoustic neuroma (vestibular schwannoma), complete congenital aplasia of the cochlea or auditory nerve (Michel aplasia / nerve agenesis), active middle/inner ear infection, or tympanic membrane perforations preventing safe intratympanic administration.
Triage Protocol & Multi-Specialty Clearance:
Dual-specialist evaluation by a neurotologist and clinical audiologist prior to issuing international medical travel confirmation.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Auditory Threshold Shifts: Potential stabilization or modest decibel (dB) gains in pure tone air and bone conduction thresholds across key conversational frequencies (500–4000 Hz).
- Speech Intelligibility: Measurable improvements in speech discrimination and word clarity in quiet and moderately noisy environments.
- Tinnitus Attenuation: Notable reduction in the loudness, intrusiveness, and severity score of co-occurring subjective tinnitus (THI scale).
- Sound Processing & Clarity: Improved perception of high-frequency environmental sounds and reduced listening fatigue.
Documented Procedural Risks & Limits:
- Post-intratympanic transient ear fullness, minor injection-site discomfort, or brief caloric vertigo/dizziness resolving within 24–48 hours.
- Rare risks: transient hemotympanum, persistent tympanic membrane micro-perforation, or temporary middle-ear effusions.
- No Guaranteed Auditory Restoration: Auditory hair cells do not spontaneously regrow in full; biological therapies cannot guarantee normal hearing restoration, especially in cases with long-standing complete auditory nerve degeneration.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Campus
Procedures performed within tertiary ENT and neuroscience hospitals accredited by NABH and JCI.
Advanced Otologic Infrastructure
Delivered in dedicated otologic operating suites utilizing high-magnification operating microscopes, HD oto-endoscopes, and calibrated soundproof audiology testing booths.
Specialized Audiology Faculty
Direct oversight by fellowship-trained neurotologists, cochlear implant surgeons, and certified clinical audiologists.
Ethics Oversight
Supervised strictly by an active Institutional Ethics Committee (IEC) registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with lead neurotologists and audiologists to review audiograms, BERA tracings, and define realistic functional expectations.
Government Medical Visa
Expedited documentation support for official Government of India Medical Visa (MED) and Medical Attendant (MED-X) approvals.
Dedicated Case Liaison
Multilingual coordinator managing private airport transfers, hospital check-in, priority testing schedules, and medical documentation.
Structured Remote Follow-Up
Scheduled virtual evaluations at Months 1, 3, 6, and 12, coordinating repeat PTA audiograms and speech clarity scores directly with your local audiologist back home.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Quiet Airport Transfers
Private, air-conditioned vehicle pick-up and drop-off designed for low-stress transit, especially for patients with concurrent vestibular imbalance or tinnitus.
Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the hospital, featuring acoustic insulation, elevator facilities, walk-in showers, and high-speed Wi-Fi.
Patient Amenities
Anti-inflammatory nutritional meal planning supervised by clinical dietitians, local SIM card registration, and 24/7 on-call nursing access.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 3 to 4 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Sensorineural Hearing Loss (SNHL)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
First-in-Human Phase 1 Clinical Trial of Systemic Autologous Cord Blood Progenitor Cells in SNHL
Baumgartner, J. E., Moore, E., Shook, D., et al. (2018). Safety of Autologous Umbilical Cord Blood Therapy for Acquired Sensorineural Hearing Loss in Children: A Phase 1 Clinical Trial. Journal of Audiology & Otology, 22(4), 209–222.
Systematic Review & Meta-Analysis of Mesenchymal Stem Cells for Sensorineural Hearing Loss
Chorath, K., Willis, M., Morton-Gonzaba, N., & Moreira, A. (2020). Mesenchymal stem cells for sensorineural hearing loss: a systematic review of preclinical studies. Molecular Biology Reports, 47(6), 4723–4736.
Neurotrophin Secretion & Functional Otic Progenitor Repair in Auditory Neuropathy
Chen, W., Jongkamonwiwat, N., Abbas, L., Eshtan, S. J., Johnson, S. L., Kuhn, S., Milo, M., Thurlow, J. K., Andrews, P. W., Marcotti, W., Moore, H. D., & Rivolta, M. N. (2012). Restoration of auditory evoked responses by human ES-cell-derived otic progenitors. Nature, 490(7419), 278–282.
Paracrine Protection of Cochlear Hair Cells & Spiral Ganglion Neurons via MSC Neurotrophins
Chang, S. Y., Jeong, H. W., Kim, E., Jung, J. Y., & Lee, M. Y. (2021). Distribution and Afferent Effects of Transplanted Mesenchymal Stem Cells on Cochlea in Acute and Chronic Neural Hearing Loss Models. BioMed Research International, 2021, 4956404.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell and biological therapies for Sensorineural Hearing Loss (SNHL) are classified as strictly investigational and experimental. They are not approved by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure. Cellular therapies cannot replace indicated standard rehabilitative devices, such as digital hearing aids or cochlear implants, in individuals with severe-to-profound deafness. Patients must continue their prescribed audiological and otological maintenance plans.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.